Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) targeting immune checkpoints are a leading immunotherapy for cancer.
• Immune checkpoints regulate immune responses and can be exploited by cancer cells to evade detection.
• Targeting these checkpoints with antibodies can restore the immune system's ability to fight cancer.

Purpose of the Study:

• To review immunotherapy methods, focusing on immune checkpoint pathways.
• To outline immune checkpoint inhibitors (ICIs) and their recent advancements.
• To discuss optimal treatment strategies for prevalent cancers using ICIs.

Main Methods:

• A narrative review of existing literature was conducted.
• The review encompassed the history, biology, and clinical applications of immune checkpoint molecules.
• Searched studies focused on current and potential immunotherapies targeting these pathways in various cancers.

Main Results:

• Key immune checkpoint molecules include CTLA-4, PD-1, PD-L1, LAG-3, TIM-3, and TIGIT.
• Therapeutic monoclonal antibodies targeting these molecules have been developed.
• Several of these antibodies are FDA-approved and in clinical use for cancer treatment.

Conclusions:

• Novel immunotherapies, including combination therapies, offer hope for metastatic cancers.
• Immune checkpoint therapy, while beneficial, can cause side effects requiring further investigation.
• More research is necessary to fully understand ICIs and optimize combination therapies for better treatment responses.